AVLN (Avalyn Pharma Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by AVLN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-17 | Robert J. Meyer | Director | A | — | — |
| 2026-05-05 | FMR LLC | 10%+ Owner | C | — | — |
| 2026-05-05 | Novo Holdings A/S | 10%+ Owner | MIXED | — | — |
| 2026-05-04 | Adam H. Golden | General Counsel | A | — | — |
| 2026-05-01 | Howard Lazarus | Chief Medical Officer | A | — | — |
| 2026-05-01 | Heather D Turner | Director | A | — | — |
| 2026-05-01 | Lyn Baranowski | Chief Executive Officer | A | — | — |
| 2026-05-01 | Douglas R Carlson | Chief Financial Officer | A | — | — |
| 2026-05-01 | Melissa Rhodes | Chief Operating Officer | A | — | — |
| 2026-05-01 | Jon Congleton | Director | A | — | — |
| 2026-05-01 | Erin Lavelle | Director | A | — | — |
| 2026-05-01 | Simeon George | 10%+ Owner | MIXED | — | — |
| 2026-05-01 | Jill Carroll | Director | MIXED | — | — |
| 2026-05-01 | Kate Haviland | Director | A | — | — |
| 2026-05-01 | Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | 10%+ Owner | C | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 3,327,734 | — |
| — | Director | 1,908,784 | — |
| — | 10%+ Owner | 1,419,298 | — |
| — | 10%+ Owner | 1,275,486 | — |
| — | 10%+ Owner | 727,585 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AVLN quote page; the site-wide leaderboard is on the insider transactions hub.